Tribute Pharmaceuticals Canada Inc. (fka TBUFF)

[djpope]

Tribute Acquires Medical Futures Inc. Expanding portfolio

This acquisition further diversifies Tribute's product portfolio in Canada through the addition of 13 marketed and 2 pipeline products. Highlights of the MFI portfolio include Durela®, Proferrin® and Resultz®.

See link below for further details.

Enjoy dp

http://finance.yahoo.com/news/tribute-pharmaceuticals-announces-acquisition-medical-122900822.html

Tribute Pharmaceuticals Announces Acquisition of Medical Futures Inc., a Canadian Specialty Pharmaceutical Company
Includes Canadian Rights to Durela(R), Proferrin(R) and 13 Additional Products
Marketwired Tribute Pharmaceuticals Canada Inc.


MILTON, ONTARIO--(Marketwired - Jun 17, 2015) - Tribute Pharmaceuticals Canada Inc. (TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that it has acquired Medical Futures Inc. ("MFI") in a transaction valued at $25 million. Financial terms of the deal include the payment of: $8.3 million in cash on closing; $5 million through the issuance of 3,723,008 common shares in the capital of Tribute; and, $5 million in the form of a one year term promissory note bearing interest at 8% annually convertible at MFI's option at any time during the term into 2,813,778 common shares of Tribute; and future contingent cash milestone payments totaling $6 million based on attainment of certain conditions expected shortly after the close of this transaction. Net Sales of MFI in the twelve month period ended March 31, 2015 were approximately $10 million. This transaction is expected to be immediately accretive. Unless otherwise indicated herein, all references to monetary amounts are in Canadian dollars.